Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit .NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin.
紐約，2024年11月20日 /PRNewswire/ -- Hoth therapeutics, Inc. (納斯達克：HOTH)，一家以患者爲中心的生物製藥公司，今天宣佈董事會批准購買最多100萬美元的比特幣。
"As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset," said Robb Knie, CEO of Hoth. "With recent approval of Bitcoin ETFs and increasing activity from institutional investors, it is a strong addition to our treasury strategy. We believe its inflation-resistant characteristics may make it a reliable asset as a functional store of value."
"隨着比特幣的持續增長，獲得投資者的關注和接受作爲主要資產類別，我們相信比特幣將作爲強大的國庫儲備資產，" Hoth的首席執行官Robb Knie說。"隨着比特幣ETF的近期批准和機構投資者日益活躍，這將是我們國庫策略的強有力補充。我們相信其抵禦通脹的特性，可能使其成爲一個可靠的有形價值儲存資產。"
About Hoth Therapeutics, Inc.
關於Hoth Therapeutics, Inc。
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit .
熱索治療公司是一家臨床階段的生物製藥公司，致力於開發創新、有影響力和開創性的治療方法，旨在改善患者的生活質量。我們是早期製藥研究和開發中的催化劑，將藥物從實驗室轉化爲臨床前和臨床測試。利用以患者爲中心的方法，我們與一支科學家、臨床醫生和意見領袖團隊合作和夥伴關係，尋找和調查具有巨大潛力的治療方案，以創造突破並豐富治療選擇。欲了解更多信息，請訪問網站。
譯文內容由第三人軟體翻譯。
